Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists

• Published in: Journal of the Endocrine Society 2021-04, Vol.5 (4), p.bvab020-bvab020
• Main Authors: Yoshida, Yuichi, Yoshida, Rika, Shibuta, Kanako, Ozeki, Yoshinori, Okamoto, Mitsuhiro, Gotoh, Koro, Masaki, Takayuki, Shibata, Hirotaka
• Format: Article
• Language: English
• Subjects: Analysis; Clinical s; Health aspects; Hyperaldosteronism; Surveys
• ISSN: 2472-1972; 2472-1972
• DOI: 10.1210/jendso/bvab020

Abstract Context Although primary aldosteronism (PA) reduces quality of life (QOL), there have been no reports on whether treatment with a mineralocorticoid receptor antagonist (MRA) improves QOL in Japanese PA patients. Objective Using the 36-Item Short-Form Health Survey (SF-36), we compared the QOL of PA patients before and after treatment and evaluated whether the effectiveness of MRAs differs by sex and serum potassium level. Methods In 50 patients diagnosed with PA (with or without hypokalemia) and treated with an MRA, the SF-36 scores, blood pressure, and clinical features were assessed before, and 3 and 6 months after treatment. Separate analyses were also conducted for males and females. Results The normative mean SF-36 score of the healthy subjects was 50. The pretreatment Role-Physical (RP) (46.7 ± 1.8, P = .019), General Health (47.1 ± 1.3, P = .042), and Role-Emotional (47.2 ± 1.7, P = .045) SF-36 subscale scores of all PA patients were significantly lower than those of healthy subjects but were improved by MRA treatment. Females with PA had a lower RP score (45.1 ± 2.2, P = .008), which was not improved by MRA treatment (46.1 ± 2.4, P = .036). In addition, PA patients with hypokalemia had a lower Mental Health SF-36 subscale score (43.2 ± 4.4, P = .041), which was improved by treatment with an MRA. Conclusion MRAs improved the QOL of Japanese PA patients, but female PA patients may be more resistant to MRAs.